Atria Wealth Solutions Inc. Has $1.75 Million Stock Position in CVS Health Corporation $CVS

Key Points

• Atria Wealth Solutions Inc. reduced its stake in CVS Health by 54%, holding 25,384 shares worth approximately $1.75 million as of the latest SEC filing.
• CVS Health reported earnings of $1.81 per share for the recent quarter, surpassing analyst expectations of $1.46, with quarterly revenue increasing by 8.4% year-over-year.
• The company declared a quarterly dividend of $0.665, which will be paid to shareholders on November 3rd, yielding an annualized rate of 3.3%.

Atria Wealth Solutions Inc. decreased its position in CVS Health Corporation (NYSE:CVS - Free Report) by 54.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,384 shares of the pharmacy operator's stock after selling 29,858 shares during the period. Atria Wealth Solutions Inc.'s holdings in CVS Health were worth $1,748,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Bell Investment Advisors Inc raised its holdings in CVS Health by 119.8% in the 1st quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock valued at $31,000 after acquiring an additional 248 shares in the last quarter. Roxbury Financial LLC grew its stake in shares of CVS Health by 78.3% in the 2nd quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 202 shares during the period. ORG Partners LLC grew its stake in shares of CVS Health by 418.9% in the 2nd quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 377 shares during the period. Saudi Central Bank bought a new stake in shares of CVS Health in the 1st quarter valued at approximately $34,000. Finally, Livelsberger Financial Advisory bought a new stake in shares of CVS Health in the 2nd quarter valued at approximately $35,000. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Stock Up 1.4%

Shares of CVS opened at $80.75 on Thursday. The firm has a market capitalization of $102.42 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 0.88 and a beta of 0.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. The business's fifty day moving average price is $73.30 and its two-hundred day moving average price is $67.92. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $81.93.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.35. The firm had revenue of $98.92 billion for the quarter, compared to analyst estimates of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business's quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the company earned $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Thursday, October 23rd. CVS Health's dividend payout ratio (DPR) is presently 74.30%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a "hold (c)" rating on shares of CVS Health in a research note on Tuesday. Truist Financial set a $92.00 price objective on CVS Health in a research note on Tuesday. Morgan Stanley upped their price objective on CVS Health from $82.00 to $89.00 and gave the company an "overweight" rating in a research note on Tuesday. Wolfe Research upped their price objective on CVS Health from $80.00 to $85.00 and gave the company an "outperform" rating in a research note on Monday, September 22nd. Finally, Zacks Research lowered CVS Health from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and a consensus price target of $81.05.

Insider Buying and Selling

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the transaction, the director directly owned 22,156 shares in the company, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.22% of the company's stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.